• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

Non-viral Vector Delivery Cell Development Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Based on our research and development experience in TCR-T cell therapy, Creative Biolabs has developed a platform for non-viral vector delivery cell development in allogeneic TCR-T cell therapy. We are confident that our manufacturing platform will facilitate the efficient development and production of a variety of TCR-T therapies.

TCR Delivery

TCR delivery refers to the process of introducing engineered TCRs into T cells to enable them to recognize and attack cancer cells or other target cells expressing specific antigens. This process is a crucial component of TCR-T cell therapy, which aims to enhance the immune response against tumors.

These aspects of TCR delivery are critical for the successful implementation and effectiveness of TCR-T cell therapies:

• TCR modifications
  
  • Genome Editing: Genome engineering strategies, such as CRISPR/Cas9, can be employed to disrupt endogenous TCR genes (TRAC and TRBC) to prevent mispairing with introduced TCRs. This enhances the expression and functionality of the engineered TCRs.
  • Murinization: Modifying TCRs by incorporating murine constant regions can improve pairing with endogenous components and enhance TCR stability and surface expression.
  • Single-Chain TCRs: The development of single-chain TCRs (scTCRs) allows for a more compact design that can facilitate better pairing and reduce mispairing with endogenous TCRs.

Fig.1 The modifications can enhance the performance and safety of the TCRs being delivered into T cells.¹

• Artificial Antigen Presenting Cells (aAPCs)

The aAPCs can be used to stimulate T cells in vitro, providing a platform for TCR discovery and expansion before the TCRs are delivered into patient-derived T cells.

• Gene Transfer Methods

The TCR genes are transferred into T cells using various methods. The most commonly used strategies for TCR gene transfer include viral vectors and electroporation techniques (non-viral methods). Lentiviral and retroviral vectors are commonly used to transduce T cells with TCR genes, allowing for stable expression of the engineered TCRs. Non-viral methods, like transposon systems, may reduce the risk of insertional mutagenesis.

Non-viral Vector Delivery Cell Development at Creative Biolabs

Streamlining the manufacturing process to reduce complexity and cost, including the use of allogeneic (off-the-shelf) TCR-T products, can make therapies more accessible. Creative Biolabs has established a non-viral vector delivery platform that operates on a transposon/transposase system. The TCR-encoding DNA is encapsulated in a plasmid in this system. The plasmid, along with an mRNA sequence for a transposase enzyme, is introduced into T cells through electroporation. The transposase then facilitates the integration of the TCR sequence from the plasmid into the T cell's genome.

Our platform allows for larger cargo sizes, enabling the delivery of both TCRs and functional enhancements to T cells. Additionally, the process requires only a specific plasmid for each TCR product and a constant mRNA sequence, thereby simplifying the manufacturing process. Furthermore, it also provides a cost-effective solution, as the transposon system offers lower and faster manufacturing costs compared to lentiviral methods.

Please contact us and we would be pleased to help you accelerate your research through our non-viral vector delivery cell development services.

Reference

1. Shafer, P., Kelly, L. M., & Hoyos, V. "Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects." Frontiers in immunology. 13 (2022): 835762.